The successful candidate will break news on an industry that has benefited tremendously, both in terms of profit and influence, from developing vaccines and treatments critical to alleviating the COVID pandemic. At the same time, the industry is fending off efforts to curb the rising costs of prescription medicines and faces increasing pushback from national regulators over drug approvals.
This reporter would break news on how companies like Pfizer and Moderna will spend the billions of dollars earned off the pandemic, including a new push for acquisitions after a long hiatus. The candidate will report on how the pharma industry is exercising its enhanced leverage with governments, in Washington and abroad, seeking to sway major policy decisions on how drugs are approved and priced, from insulin to Alzheimer’s treatments.
The reporter would be deeply sourced among pharmaceutical and biotech executives, U.S. government health officials and industry investors. The preferred location for the role is New York.
About the Role
As our U.S. Pharmaceutical Industry Reporter, you will:
About You
To be our U.S. Pharmaceutical Industry Reporter, you will likely have:
(Internal candidates: Please note this position is incorrectly listed as being in the EIC job family).
Please note, the deadline for applications is Sunday 5th June 2022.
To apply, go here.
The Star Tribune is seeking an accomplished, motivated and versatile journalist and leader to shape…
The Deputy AME-Business is responsible for the development and planning of coverage on all Newsday…
CNBC.com managing editor Jeff McCracken announced Friday the following promotions: In San Francisco, Ari Levy has…
This Newsday reporter will cover Long Island’s commercial real estate market and the region’s evolving…
The New York Times is looking for a versatile editor to edit enterprise and feature…
International editor Matt Lamers is leaving Marijuana Business Daily. He has been there for seven years. Lamers…